IKT

Dopo l'orario di chiusura: 1.36 0.06 +4.62%

Inhibikase Therapeutics Inc (IKT)

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Inhibikase Therapeutics Inc Stock (IKT) Company Profile

Inhibikase Therapeutics Inc

678-392-3419

3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA

Prossima data di guadagno

Ultimi documenti SEC

IKT's Discussions on Twitter

Inhibikase Therapeutics Inc Borsa (IKT) Ultime notizie

Inhibikase Therapeutics Inc Azioni (IKT) Dati Finanziari

Inhibikase Therapeutics Inc (IKT)

Inhibikase Therapeutics Inc Stock (IKT) Company Profile

Inhibikase Therapeutics Inc Borsa (IKT) Ultime notizie

Fennec Pharmaceuticals (NASDAQ:FENC) & Inhibikase Therapeutics (NYSE:IKT) Head to Head Review - Defense World

Ieq Capital LLC Purchases 2,616 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) - MarketBeat

Just the Facts: Imugene receives Orphan Drug Designation for VAXINIA from FDA - Proactive Investors Australia

J.W. Cole Advisors Inc. Has $225,000 Holdings in InvenTrust Properties Corp. (NYSE:IVT) - Defense World

Inogen (NASDAQ:INGN) Is In A Strong Position To Grow Its Business - Yahoo Finance

Innovative Industrial Properties (NYSE:IIPR) Hits New 1-Year High at $137.91 - MarketBeat

Had You Purchased Incyte in 2004, Here’s Your Result - MMJ Stock Watch

INVX underperforms with a -2.86 decrease in share price - US Post News

Ratios Uncovered: Breaking Down Ironwood Pharmaceuticals Inc (IRWD)’s Trailing Twelve Months Metrics - The Dwinnex

Incyte Corp. (INCY) looking to reclaim success with recent performance - SETE News

InvenTrust Properties Corp. (NYSE:IVT) Short Interest Down 5.5% in August - Defense World

Get in on Invesco Ltd’s (IVZ) buy-in window today! - SETE News

The Escalator: Imre, Kyverna Therapeutics, The Bloc and more - MM+M Online

InnovAge (NASDAQ:INNV) Trading Up 4.2% - Defense World

Imugene (ASX:IMU) achieves FDA Orphan Drug Designation for VAXINIA - Kalkine Media

Incyte stock downgraded amid looming patent cliff concerns By Investing.com - Investing.com Canada

Insider Selling: InnovAge Holding Corp. (NASDAQ:INNV) Insider Sells 4,372 Shares of Stock - Defense World

InnovAge holding corp. executive sells over $70k in stock By Investing.com - Investing.com UK

Incyte DowngradedAnalyst Notes Intense Competition, Particularly In Larger Markets - Yahoo Finance

Incyte (NASDAQ:INCY) Stock Price Down 1.9% - MarketBeat

Truist downgrades Incyte to "hold" on doubts of near-term prospects - XM

Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga

Victory Capital Management Inc. Buys 52,523 Shares of Innoviva, Inc. (NASDAQ:INVA) - Defense World

Incyte (NASDAQ:INCY) Receives Market Perform Rating from JMP Securities - Defense World

Imunon (NASDAQ:IMNN) Shares Up 5.6% - Defense World

Imugene gets crucial FDA nod for bile tract cancer drug - The West Australian

Imugene secures FDA orphan drug designation for bile tract cancer treatment By Proactive Investors - Investing.com Australia

Imugene Gains FDA Orphan Status for Cancer Therapy - TipRanks

Ratio Review: Analyzing Innovex International Inc. (INVX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

What was Ironwood Pharmaceuticals Inc (IRWD)’s performance in the last session? - US Post News

Victory Capital Management Inc. Sells 273,806 Shares of Ingredion Incorporated (NYSE:INGR) - Defense World

Ironwood Pharmaceuticals Inc (IRWD) Becoming More Attractive for Investors - Knox Daily

Investing in Incyte Corp. (INCY): What You Must Know - Knox Daily

Incyte closes 5% higher bolstered by Zynyz data, Guggenheim note - MSN

Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch

Illinois Tool Works Inc. stock outperforms competitors on strong trading day - MarketWatch

Healthy Upside Potential: Ironwood Pharmaceuticals Inc (IRWD) - SETE News

Should Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Investors Be Concerned? - Stocks Register

Instil Bio price target raised to $120 from $40 at H.C. Wainwright - TipRanks

Forsta AP Fonden Sells 13,900 Shares of Incyte Co. (NASDAQ:INCY) - Defense World

Victory Capital Management Inc. Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World

Illinois Tool Works (NYSE:ITW) Lifted to Buy at StockNews.com - Defense World

What Is Illinois Tool Works Inc.'s (NYSE:ITW) Share Price Doing? - Simply Wall St

Rathbones Group PLC Increases Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) - MarketBeat

Incyte’s Retifanlimab (Zynyz ® ) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium - NTB Kommunikasjon

StockNews.com Upgrades Illinois Tool Works (NYSE:ITW) to Buy - MarketBeat

IKT (Inhibikase Therapeutics) Operating Cash Flow per Share : $-2.81 (TTM As of Mar. 2024) - GuruFocus.com

IKT (Inhibikase Therapeutics) Cash Flow from Operations : $-15.98 Mil (TTM As of Mar. 2024) - GuruFocus.com

IKT (Inhibikase Therapeutics) Cyclically Adjusted Book per Share : $0.00 (As of Mar. 2024) - GuruFocus.com

IKT (Inhibikase Therapeutics) 50-Day SMA : $1.41 (As of Aug. 18, 2024) - GuruFocus.com

IKT (Inhibikase Therapeutics) Book Value per Share : $1.05 (As of Mar. 2024) - GuruFocus.com

Inhibikase Therapeutics Inc Azioni (IKT) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a IKT